Company Filing History:
Years Active: 2021
Title: Michelle Hortter: Innovator in Bispecific Antigen Binding Proteins
Introduction
Michelle Hortter is a prominent inventor based in Camarillo, California. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antigen binding proteins. Her innovative work has the potential to impact therapeutic approaches for various diseases.
Latest Patents
Michelle Hortter holds a patent for "Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof." This invention focuses on antigen binding proteins that specifically target TL1A, including bispecific antibodies that can bind to both TL1A and TNF-alpha. The patent describes various formats for these bispecific antibodies, including tetrameric immunoglobulin formats and IgG-scFv fusions. The applications of these proteins extend to pharmaceutical formulations, showcasing their potential in medical treatments.
Career Highlights
Michelle is currently employed at Amgen Inc., a leading biotechnology company known for its innovative therapies. Her work at Amgen has allowed her to collaborate with other talented professionals in the field, further enhancing her contributions to biotechnology.
Collaborations
Some of her notable coworkers include Hailing Hsu and Gunasekaran Kannan. Their collaborative efforts have likely contributed to the advancement of research and development in their respective projects.
Conclusion
Michelle Hortter's innovative work in bispecific antigen binding proteins exemplifies the impact of biotechnology on modern medicine. Her contributions continue to pave the way for new therapeutic solutions.